(Q43890466)

27 November 2017

title

Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients (English)

1 reference

27 November 2017

1 reference

1 reference

1 reference

Ruth Kitzes-Cohen

1

1 reference

27 November 2017

Dina Farin

series ordinal

2

1 reference

27 November 2017

Guillermo Piva

series ordinal

3

1 reference

27 November 2017

Sylvie Anne De Myttenaere-Bursztein

series ordinal

4

1 reference

27 November 2017

publication date

1 February 2002

1 reference

International Journal of Antimicrobial Agents

27 November 2017

published in

1 reference

27 November 2017

volume

19

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

105-110

1 reference

Meropenem: a review of its use in patients in intensive care

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Continuous infusion versus intermittent administration of meropenem in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem in patients with liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

The pharmacokinetics of meropenem in surgical patients with moderate or severe infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem in patients with intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Clinical pharmacokinetics of meropenem after the first and tenth intramuscular administration

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem in subjects with various degrees of renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetics of meropenem in subjects with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900474-5

7 January 2021

10.1016/S0924-8579(01)00474-5

Identifiers

DOI

1 reference

release_qnodiqrve5h3zmkfo3drbuh5ii

27 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qnodiqrve5h3zmkfo3drbuh5ii

24 November 2022

mapped directly with Wikidata item

1 reference